Arvee Laboratories Q4 FY26 Earnings Preview & Outlook

Wed Mar 25 2026

Arvee Laboratories (India) latest news: Arvee Laboratories (India) Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Arvee Laboratories (India) was listed on the National Stock Exchange (NSE) on 22-Mar-2021. Arvee Laboratories (India) share has its face value of 10 per share, and its NSE symbol is ARVEE. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

Table of Contents

Arvee Laboratories (India) Q4 Results 2026 Preview

Arvee Laboratories (India) Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 10-14% YoY increase compared to the same quarter last year.
Profit After Tax, or PAT, is projected to rise 11-16% YoY.
EBITDA to rise 10-15%.
Arvee Laboratories (India) is expected to show Moderate Growth Expected in its revenue.

Click and Sign Up to Get Live Updates on Q4 Results

Arvee Laboratories (India) Share Performance

Over the past six months, Arvee Laboratories (India) share price has Up by 20% to 144.75.
Moreover, over the past year, the stock has Up by 34%
Despite this weak short-term performance, Arvee Laboratories (India) stock has delivered a financially sound 160% return over the past 5 years.
As of today, 25-03-2026, the Arvee Laboratories (India) share price is trading at 144.75 per share.

Key Factors to Watch for Arvee Laboratories (India) Q4 Results FY26

Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

Visit Univest app or website to check more Arvee Laboratories (India) latest news to make an informed investment decision.

About Arvee Laboratories (India)

Arvee Laboratories manufactures pharmaceutical formulations and medicines for domestic and export markets. The company focuses on quality manufacturing, regulatory compliance, and expanding its product portfolio, benefiting from growing healthcare demand and increasing opportunities in regulated and emerging global markets.

Visit Univest app or website to check more Arvee Laboratories (India) latest news to make an informed investment decision.

Final Thoughts

Arvee Laboratories (India) is gear up to announce its Q4 FY26 results. Analysts expect 10-14% revenue growth, a 11-16% rise in PAT, and a 10-15% rise in EBITDA. Arvee Laboratories (India) focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Arvee Laboratories (India) Q4 results FY26.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.